David Arthur, Salarius CEO
FDA lifts partial hold on Salarius' Ewing sarcoma drug trial
Houston biotech Salarius Pharmaceuticals has received some positive news from the FDA.
Salarius announced Tuesday that the agency removed a partial clinical hold from its …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.